All In Biotech

Drug Trial Radar · NCT07722767

A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients

A Phase 1b Dose Escalation and Dose Expansion Study of CLN 049 in Combination With Azacitidine and Venetoclax for the Treatment of Adult Patients With Newly Diagnosed, Acute Myeloid Leukemia

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

90

Planned (sponsor's estimate)

Start

Oct 15, 2026

Primary completion

Sep 30, 2027

Study completion Aug 31, 2030

Sponsor

Lead sponsor
Cullinan Therapeutics Inc.Industry
Sponsor type
Industry
First posted
Jul 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 1b, open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of intravenously (IV) administered CLN-049 in combination with azacitidine (Aza) and venetoclax (Ven) in patients with newly diagnosed (ND) AML.

Conditions

  • AML (Acute Myeloid Leukemia)

Interventions

  • CLN-049Drug

    CLN-049 will be initiated using two step-up doses (SUDs), followed by the first target dose (TD) one week later, and weekly thereafter.

  • AzacitidineDrug

    Azacitidine 75 mg/m2 will initially be administered sub-cutaneous or intravenous on days 1 through 7 of a 28-day cycle

  • VenetoclaxDrug

    Venetoclax will initially be administered orally on days 1 through 28 of a 28-day cycle and then reduced to days 1 through 14 in consolidation cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and severity of adverse events (AEs)/adverse events of special interest (AESIs)/serious adverse events (SAEs) [safety and tolerability] of CLN-049 combined with azacitidine and venetoclaxTime frame: 48 weeks
  2. Determine recommended dose/schedule of CLN-049 in combination with azacitidine and venetoclaxTime frame: 48 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California

  • University of Miami Health System

    Miami, Florida

  • Emory University Hospital

    Atlanta, Georgia

  • New York University Langone Health

    New York, New York

  • MD Anderson

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.